Varex Imaging
VREXNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $18.45 Prior regular-session close from the quote source.
- $18.39–$18.48 Regular-session low and high so far today.
- 406.9K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Nov 17 projected Projected for 2026-11-17 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $9.09–$18.63 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own VREX if embedded OEM demand and higher-value detector/tube technology translate back into GAAP operating profit and cash, not merely stable sales.
VREX price history
Loading recent earnings…
Investment thesis
What must happen next
Because Varex components are designed into customer X-ray systems, OEM integration should keep demand resilient unless customers redesign platforms around alternative suppliers or internal components.HoldingMateriality: High
GAAP annual revenue was $844.6 million in FY2025 versus $811.0 million in FY2024, showing the business did not collapse despite weak profitability. If embedded demand holds, revenue can support a margin recovery; if OEMs switch or insource, the revenue base loses its strategic value.
Watch: A major medical imaging OEM qualifies a competing X-ray tube or detector supplier across a new platform generation.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue was $844.6 million in FY2025 versus $811.0 million in FY2024, showing the business did not collapse despite.
Open source ↗Varex’s breadth in higher-value imaging components, including flat panel and photon-counting detectors, should support gross profit if customers continue to pay for performance rather than treating components as commodities.StrengtheningMateriality: High
GAAP annual gross profit improved to $290.5 million in FY2025 from $256.9 million in FY2024. The company needs pricing and mix power at the gross-profit line before any operating leverage can reach shareholders.
Watch: OEMs shift photon-counting or advanced detector value capture in-house rather than buying from Varex.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit improved to $290.5 million in FY2025 from $256.9 million in FY2024.
Open source ↗The business model only creates equity value if Varex converts specialized engineering and manufacturing scale back into GAAP operating profit; FY2025 suggests fixed costs, mix, or execution are currently overpowering the component franchise.WeakeningMateriality: Medium
Varex generated positive GAAP annual operating income of $88.2 million in FY2022, $77.1 million in FY2023, and $32.1 million in FY2024, showing the model has been profitable before. A component moat that cannot cover operating costs is not a shareholder moat; operating-profit recovery is the key proof point.
Watch: New detector, tube, or system programs require sustained engineering and manufacturing spending without offsetting volume or pricing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Varex generated positive GAAP annual operating income of $88.2 million in FY2022, $77.1 million in FY2023, and $32.1 million in.
Open source ↗Varex must keep converting orders into operating cash through OEM cycles, because positive cash generation gives management time to fix margins without issuing equity or over-borrowing.StrengtheningMateriality: Medium
GAAP annual operating cash flow was positive at $41.7 million in FY2025 despite a GAAP net loss. Cash conversion determines whether the turnaround accrues to shareholders or is consumed by financing needs.
Watch: OEM order volatility forces inventory builds or receivable stretch that consume cash before earnings recover.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was positive at $41.7 million in FY2025 despite a GAAP net loss.
Open source ↗The balance sheet gives Varex some turnaround runway, but the thesis weakens if liabilities stop declining or refinancing needs force management to prioritize creditors over product investment.HoldingMateriality: Medium
Total liabilities declined to $620.8 million at FY2025 period end from $670.4 million at FY2024 period end. Leverage and liquidity shape how much of any operating recovery belongs to common shareholders.
Watch: Debt refinancing occurs at materially higher cost or with restrictive covenants before operating income recovers.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Total liabilities declined to $620.8 million at FY2025 period end from $670.4 million at FY2024 period end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Because Varex components are designed into customer X-ray systems, OEM integration should keep demand resilient unless customers redesign platforms around alternative suppliers or internal components. If embedded demand holds, revenue can support a margin recovery; if OEMs switch or insource, the revenue base loses its strategic value.
Varex’s breadth in higher-value imaging components, including flat panel and photon-counting detectors, should support gross profit if customers continue to pay for performance rather than treating components as commodities. The company needs pricing and mix power at the gross-profit line before any operating leverage can reach shareholders.
The business model only creates equity value if Varex converts specialized engineering and manufacturing scale back into GAAP operating profit; FY2025 suggests fixed costs, mix, or execution are currently overpowering the component franchise. A component moat that cannot cover operating costs is not a shareholder moat; operating-profit recovery is the key proof point.
Varex must keep converting orders into operating cash through OEM cycles, because positive cash generation gives management time to fix margins without issuing equity or over-borrowing. Cash conversion determines whether the turnaround accrues to shareholders or is consumed by financing needs.
The balance sheet gives Varex some turnaround runway, but the thesis weakens if liabilities stop declining or refinancing needs force management to prioritize creditors over product investment. Leverage and liquidity shape how much of any operating recovery belongs to common shareholders.
All standing thesis claims
Original report summary
embedded OEM demand and higher-value detector/tube technology translate back into GAAP operating profit and cash, not merely stable sales.
Bull case and bear case
Bull case and bear case for Varex Imaging
Where the evidence on Varex Imaging disagrees: Mixed on the latest evidence (Nov 8, 2026). Of its 5 thesis points, 2 strengthening, 2 holding and 1 weakening.
Bull case: what the evidence supports
Because Varex components are designed into customer X-ray systems, OEM integration should keep demand resilient unless customers redesign platforms around alternative suppliers or internal components.
Varex’s breadth in higher-value imaging components, including flat panel and photon-counting detectors, should support gross profit if customers continue to pay for performance rather than treating components as commodities.
Varex must keep converting orders into operating cash through OEM cycles, because positive cash generation gives management time to fix margins without issuing equity or over-borrowing.
The balance sheet gives Varex some turnaround runway, but the thesis weakens if liabilities stop declining or refinancing needs force management to prioritize creditors over product investment.
Bear case: what the evidence questions
The business model only creates equity value if Varex converts specialized engineering and manufacturing scale back into GAAP operating profit; FY2025 suggests fixed costs, mix, or execution are currently overpowering the component franchise.
Thesis-Break Engine
Thesis-break watch · Varex Imaging
No break has crossed Varex Imaging’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedOther material event.
Varex Imaging filed an SEC 8-K on 2026-10-22: Other material event. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Varex Imaging filed an SEC 8-K on 2026-08-10: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Varex Imaging filed an SEC 8-K on 2026-08-10: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A major medical imaging OEM qualifies a competing X-ray tube or detector supplier across a new platform generation.
- OEMs shift photon-counting or advanced detector value capture in-house rather than buying from Varex.
- New detector, tube, or system programs require sustained engineering and manufacturing spending without offsetting volume or pricing.
- OEM order volatility forces inventory builds or receivable stretch that consume cash before earnings recover.
- Debt refinancing occurs at materially higher cost or with restrictive covenants before operating income recovers.
VREX news
Loading headlines…
Financial statements
VREX income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
VREX: quick answers
- When does Varex Imaging (VREX) report earnings next?
- Varex Imaging's next results are projected for November 17, 2026, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on August 10, 2026. Earnings calendar
- What is VREX's short interest?
- As of October 30, 2026, 2.0M VREX shares were sold short, 4.83% of its shares outstanding, up 24.7% from the count before. At the stock's average daily volume that is 3.2 days to cover. FINRA publishes the count twice a month. VREX short interest history
